

# Bausch Health Announces Third-Quarter 2023 Results

November 02, 2023

- **Revenue of \$2.24 billion, up 9% on both a Reported and Organic<sup>1</sup> basis**
- **Year-over-year revenue growth in all segments on both a Reported and Organic Basis**
- **GAAP Net Loss Attributable to Bausch Health Companies Inc. of \$378 Million**
- **Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)<sup>1</sup> of \$830 Million, up 8%**
- **Provides updated full-year Revenue and Adjusted EBITDA (non-GAAP)<sup>1</sup> guidance**
- **Received U.S. Food and Drug Administration ("FDA") approval for CABTREO™ (IDP-126), the first and only FDA-approved fixed-dose, triple-combination topical treatment for acne**

LAVAL, QC, November 2, 2023 – Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third-quarter 2023 financial results and other key updates from the quarter.

"We are pleased with our solid third-quarter performance, as each of our business segments posted year- over-year revenue growth on both a reported and organic basis. We remain focused on advancing our R&D pipeline, strengthening our balance sheet and executing on our commercial strategies to drive global growth," said Thomas J. Appio, Chief Executive Officer, Bausch Health.

## **Bausch Health (excl. B+L) R&D Update**

- **RED-C:** prevention and delay of first episode of hepatic encephalopathy
  - Enrollment of two global Phase 3 trials on track and expected to be completed in Q1 2024
- **Amiselimod (S1P modulator):** treatment of mild to moderate Ulcerative Colitis
  - Phase 2 study completed enrollment in July 2023 and induction portion of the study is expected to be completed in Q4 2023
- **CABTREO™:** first triple combination product for the treatment of acne vulgaris
  - Received FDA approval on October 20, 2023
  - Commercial launch expected in Q1 2024
  - New Drug Submission was submitted to Health Canada on May 30, 2023
- **Clear + Brilliant® Touch:** fractionated laser device for skin rejuvenation
  - Planned regulatory submissions on track for Europe, Canada, and Asia Pacific markets in 2024
- **Next Generation Fraxel®:** fractionated laser device for skin resurfacing
  - FDA submission planned in Q1 2024 and approval is expected 1H 2024

## **Third Quarter 2023 Revenue Performance**

Total reported revenues were \$2.24 billion for the third quarter of 2023, compared with \$2.05 billion in the third quarter of 2022, an increase of \$192 million, or 9%. Excluding the impact of

foreign exchange of \$6 million and acquisitions, divestitures, and discontinuations of \$19 million, revenue increased by 9% organically<sup>1</sup> compared with the third quarter of 2022.

[Read More](#)

View original release here:

<https://www.accesswire.com/viewarticle.aspx?id=798524>



**Investor Inquiries**

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

877-281-6642

514-856-3855 (Canada)

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to  
the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights  
reserved. MTB.0230.USA.18 V2.0

**Media inquiries**

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)

908-569-3692

**CALIFORNIA RESIDENTS: DO NOT SELL MY  
PERSONAL INFORMATION**